Abpro Holdings (ABPO) Share-based Compensation (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Share-based Compensation came in at $2.1 million in Q1 2026, up 308.4% YoY from $512000.0 in Q1 2025, and up 531.72% on a QoQ basis from $331000.0 in Q4 2025.
Abpro Holdings (ABPO) Share-based Compensation (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Share-based Compensation data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 308.4% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 11.46% YoY) and the FY2025 annual result came in at $2.3 million, up 21.22% from the prior year.
- Share-based Compensation grew to $2.1 million in Q1 2026, from $331000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.3 million in Q4 2023 to a low of $154000.0 in Q2 2025.
- A 5-year average of $724409.1 and a median of $415000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 82.82% — and 2026, when it jumped 308.4%.
- Tracing ABPO's Share-based Compensation over 5 years: stood at $362500.0 in 2022, then soared by 535.86% to $2.3 million in 2023, then plunged by 82.82% to $396000.0 in 2024, then slipped by 16.41% to $331000.0 in 2025, then jumped by 531.72% to $2.1 million in 2026.
- The last three Share-based Compensation figures came in at $2.1 million (Q1 2026), $331000.0 (Q4 2025), and $286000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 208,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.09 Mn |
| Mar 31, 2026 | 2.09 Mn |
| Dec 31, 2025 | 331,000.00 |
| Dec 31, 2025 | 331,000.00 |
| Sep 30, 2025 | 286,000.00 |
| Sep 30, 2025 | 286,000.00 |
| Jun 30, 2025 | 154,000.00 |
| Jun 30, 2025 | 154,000.00 |
| Mar 31, 2025 | 512,000.00 |
| Mar 31, 2025 | 512,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 553,000.00 |
| Jun 30, 2024 | 553,000.00 |
| Mar 31, 2024 | 563,000.00 |
| Mar 31, 2024 | 563,000.00 |
| Dec 31, 2023 | 2.31 Mn |
| Dec 31, 2023 | 2.31 Mn |